Reference priceRUB ₽57,750.00Original source price: INR 52,500.00. Converted estimates are available by currency selection.
| Brand | Jakavi |
|---|---|
| Manufacturer | Novartis Pharmaceuticals |
| Prescription required | Yes |
Jakavi 5mg comprimidos,1 x 56(Ruxolitinib)
Ruxolitinib
Description
Jakavi 5mg comprimidos,1 x 56(Ruxolitinib) is a medicine catalog record in the MediPriceHub database. Active ingredient: Ruxolitinib. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: Novartis Pharmaceuticals. Therapeutic category: Medicine Library > Oncology Medicines > Platelet-increasing drugs. Pack information: 5 / 56. Origin country or market: Spain. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.Benefits
OPZELURA is a Janus kinase (JAK) inhibitor indicated for: the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older. Limitations of Use Use of OPZELURA in combination with therapeutic biologics, other JAK inhibitors or potent immunosuppressants such as azathioprine or cyclosporine is not recommended. 1.1 Atopic Dermatitis OPZELURA is indicated for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. 1.2 Nonsegmental Vitiligo OPZELURA is indicated for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older. 1.3 Limitations of Use Use of OPZELURA in combination with therapeutic biologics, other Janus kinase (JAK) inhibitors, or potent immunosuppressants such as azathioprine or cyclosporine is not recommended.How to Use
Use Ruxolitinib under the supervision of a qualified healthcare professional. Take it by mouth only according to the approved label and the dose prescribed by a qualified healthcare professional. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.Specification
Active ingredient: Ruxolitinib. Pack size: 5 / 56. Pack unit: box. Manufacturer: Novartis Pharmaceuticals. Origin country: Spain. Source category: Medicine Library > Oncology Medicines > Platelet-increasing drugs. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.Side Effects
Cancer medicines may cause fatigue, nausea, vomiting, diarrhea or constipation, appetite changes, mouth sores, rash, changes in blood counts, infection risk, liver or kidney test changes, bleeding risk, neuropathy, infusion reactions, or organ-specific toxicity depending on the medicine. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, confusion, serious bleeding, signs of infection, or rapidly worsening symptoms. The approved local prescribing information is the controlling source for the complete adverse-reaction profile.Эта информация носит справочный характер. Перед применением лекарства проконсультируйтесь с медицинским специалистом.